{
    "organizations": [],
    "uuid": "89ccca362d53ebc8587d4155cdc566ad7ea6ae88",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novavax-sees-phase-2-trial-of-nano/brief-novavax-sees-phase-2-trial-of-nanoflu-vaccine-to-begin-in-q3-2018-idUSFWN1QI1MJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Novavax Inc:\n* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018\n* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 1/2 CLINICAL TRIAL IN OLDER ADULTS OF ITS NANOFLU RECOMBINANT INFLUENZA VACCINE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-01T05:46:00.000+02:00",
    "crawled": "2018-03-01T21:17:13.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "novavax",
        "inc",
        "say",
        "phase",
        "trial",
        "nanoflu",
        "vaccine",
        "expected",
        "begin",
        "q3",
        "announces",
        "positive",
        "result",
        "phase",
        "clinical",
        "trial",
        "older",
        "adult",
        "nanoflu",
        "recombinant",
        "influenza",
        "vaccine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}